ASLAN Pharmaceuticals Limited
ASLNNASDAQHealthcare
$0.60
$-0.10(-14.27%)
Market Cap$777122375
P/E Ratio—
52W High$17.04
52W Low$0.475
ASLAN Pharmaceuticals Limited (ASLN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ASLN · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $12.00M | $0.00M | $0.00M | $0.00M | $3.00M |
| Cost of Revenue | $0.35M | $0.33M | $0.28M | $0.30M | $0.41M |
| Gross Profit | $11.65M | ($0.33M) | ($0.28M) | ($0.30M) | $2.59M |
| Gross Margin %(computed) | 97.10% | — | — | — | 86.42% |
| Operating Expenses | |||||
| R&D Expenses | $42.50M | $38.00M | $22.02M | $9.31M | $16.59M |
| G&A Expenses | $13.24M | $9.88M | $11.83M | $7.17M | $8.51M |
| Total Operating Expenses | $55.39M | $47.88M | $33.85M | $16.48M | $48.17M |
| Operating Income | ($43.74M) | ($47.88M) | ($33.85M) | ($16.48M) | ($45.58M) |
| Operating Margin %(computed) | -364.46% | — | — | — | — |
| Interest Income | $0.40M | $0.35M | $0.00M | $0.00M | $0.15M |
| Interest Expense | $4.33M | $3.68M | $1.86M | $1.25M | $0.90M |
| Income Before Tax | ($44.09M) | ($51.28M) | ($31.59M) | ($16.97M) | ($46.66M) |
| Income Tax Expense | $0.13M | $0.10M | $3.12M | $0.93M | $0.41M |
| Net Income | ($44.22M) | ($51.38M) | ($34.71M) | ($17.91M) | ($47.07M) |
| Net Margin %(computed) | -368.50% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-10.76 | $-14.72 | $-10.64 | $-9.32 | $-29.00 |
| Wtd Avg Shares | 4.11M | 3.49M | 3.26M | 1.92M | 1.62M |
| EBITDA | ($39.40M) | ($47.28M) | ($29.45M) | ($15.43M) | ($45.31M) |
| EBITDA Margin %(computed) | -328.36% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more ASLAN Pharmaceuticals Limited data
About ASLAN Pharmaceuticals Limited (ASLN) Income Statement
ASLAN Pharmaceuticals Limited (ASLN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, ASLN reported revenue of $0.01B, gross profit of $0.01B (gross margin 97.10%), and net income of ($0.04B) — a net profit margin of -368.50%.
Frequently asked questions
ASLN · 4 questionsASLAN Pharmaceuticals Limited (ASLN) reported revenue of $0.01B for 2023, up —% year-over-year.
ASLN revenueASLN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09